Michal Kicinski
Overview
Explore the profile of Michal Kicinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buhrer E, Kicinski M, Pe M, Coens C, Eggermont A
Lancet Oncol
. 2024 Dec;
25(12):e618.
PMID: 39637891
No abstract available.
2.
Musoro J, Sleurs C, Rowsell A, Suciu S, Kicinski M, Chantziara S, et al.
Pediatr Blood Cancer
. 2024 Nov;
72(2):e31446.
PMID: 39616416
Purpose: Survivors of childhood cancer can suffer from long-term sequelae or decline in quality of life (QoL), for which careful and standardized selection of outcome measures become more important. This...
3.
Domenech C, Kicinski M, De Moerloose B, Piette C, Chahla W, Kornreich L, et al.
Hemasphere
. 2024 Nov;
8(11):e70025.
PMID: 39540141
Here, we report the results of the prospective cohort study EORTC-CLG 58081 and compare them to the control arm of the randomized phase 3 trial EORTC-CLG 58951, on which treatment...
4.
Eggermont A, Kicinski M, Blank C, Mandala M, Long G, Atkinson V, et al.
Eur J Cancer
. 2024 Sep;
211:114327.
PMID: 39288737
Methods: We randomized 1019 patients to receive pembrolizumab 200 mg or placebo, intravenously every 3 weeks for a total of 18 doses. RFS in the overall population and in the...
5.
Buhrer E, Kicinski M, Mandala M, Pe M, Long G, Atkinson V, et al.
Lancet Oncol
. 2024 Aug;
25(9):1202-1212.
PMID: 39146951
Background: In the European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 study, adjuvant pembrolizumab improved recurrence-free survival and distant-metastasis-free survival in patients with resected stage III melanoma. Earlier...
6.
Kimura S, Park C, Montefiori L, Iacobucci I, Polonen P, Gao Q, et al.
Cancer Discov
. 2024 Jun;
14(10):1838-1859.
PMID: 38916500
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand...
7.
Efficace F, Kicinski M, Coens C, Suciu S, van der Velden W, Noppeney R, et al.
Blood
. 2024 May;
144(5):541-551.
PMID: 38717861
We hypothesized that fit older patients with acute myeloid leukemia (AML) treated with decitabine (DEC) would report better health-related quality of life (HRQoL) outcomes than those receiving intensive chemotherapy (IC)....
8.
Kennedy O, Glassee N, Kicinski M, Blank C, Long G, Atkinson V, et al.
Eur J Cancer
. 2024 Feb;
201:113585.
PMID: 38402687
Background: Pain is common in patients with cancer. The World Health Organisation recommends paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) for mild pain and combined with other agents for moderate/severe pain....
9.
Eggermont A, Kicinski M, Blank C, Mandala M, Long G, Atkinson V, et al.
NEJM Evid
. 2024 Feb;
1(11):EVIDoa2200214.
PMID: 38319852
BACKGROUND: In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free survival than placebo in patients...
10.
de Ville de Goyet M, Kicinski M, Suciu S, Vandecruys E, Uyttebroeck A, Ferster A, et al.
Discov Oncol
. 2024 Jan;
15(1):20.
PMID: 38285235
Survival after childhood acute lymphoblastic leukemia (ALL) has increased over the last 40 years with an overall survival above 90%. Survivors may experience neurological late effects secondary to chemotherapy and...